CN102781442B - 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法 - Google Patents

使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法 Download PDF

Info

Publication number
CN102781442B
CN102781442B CN201080057504.7A CN201080057504A CN102781442B CN 102781442 B CN102781442 B CN 102781442B CN 201080057504 A CN201080057504 A CN 201080057504A CN 102781442 B CN102781442 B CN 102781442B
Authority
CN
China
Prior art keywords
nefopam
application
catenin
medicine
cicatrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080057504.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102781442A (zh
Inventor
B·A·阿尔曼
R·普恩
H·洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44166687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102781442(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Priority to CN201610027616.7A priority Critical patent/CN105687185B/zh
Publication of CN102781442A publication Critical patent/CN102781442A/zh
Application granted granted Critical
Publication of CN102781442B publication Critical patent/CN102781442B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
CN201080057504.7A 2009-12-15 2010-12-15 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法 Expired - Fee Related CN102781442B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610027616.7A CN105687185B (zh) 2009-12-15 2010-12-15 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28663309P 2009-12-15 2009-12-15
US61/286,633 2009-12-15
PCT/CA2010/002014 WO2011072394A1 (en) 2009-12-15 2010-12-15 METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610027616.7A Division CN105687185B (zh) 2009-12-15 2010-12-15 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Publications (2)

Publication Number Publication Date
CN102781442A CN102781442A (zh) 2012-11-14
CN102781442B true CN102781442B (zh) 2016-02-17

Family

ID=44166687

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080057504.7A Expired - Fee Related CN102781442B (zh) 2009-12-15 2010-12-15 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
CN201610027616.7A Expired - Fee Related CN105687185B (zh) 2009-12-15 2010-12-15 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610027616.7A Expired - Fee Related CN105687185B (zh) 2009-12-15 2010-12-15 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法

Country Status (10)

Country Link
US (4) US8957107B2 (https=)
EP (1) EP2512468B1 (https=)
JP (1) JP5792185B2 (https=)
KR (1) KR101753439B1 (https=)
CN (2) CN102781442B (https=)
BR (1) BR112012014471A2 (https=)
CA (1) CA2782472C (https=)
DK (1) DK2512468T3 (https=)
ES (1) ES2594900T3 (https=)
WO (1) WO2011072394A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782472C (en) * 2009-12-15 2019-04-16 The Hospital For Sick Children Method of treating scars and beta-catenin-mediated disorders
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN118105343A (zh) * 2018-06-01 2024-05-31 伊特里恩治疗有限公司 特加维因和相关化合物的制剂
CN110638780A (zh) * 2019-09-11 2020-01-03 华益药业科技(安徽)有限公司 一种盐酸奈福泮片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101002756A (zh) * 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
CN101171004A (zh) * 2005-04-04 2008-04-30 索塞R&D有限公司 奈福泮及其类似物的治疗用途
WO2009053742A2 (en) * 2007-10-25 2009-04-30 Sosei R & D Limited Salts of nefopam and their use in therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
AU2003295171B2 (en) 2002-12-20 2007-09-06 Arakis Ltd. Benzoxazocines and their use as monoamine-reuptake inhibitors
GB0330049D0 (en) 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
GB2413322A (en) 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
CA2558741A1 (en) 2004-04-21 2005-11-03 Sosei R&D Ltd. Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
CN1569004A (zh) * 2004-05-13 2005-01-26 南昌弘益科技有限公司 盐酸奈福泮滴丸及其制备方法
FR2880275B1 (fr) 2005-01-06 2007-04-13 Biocodex Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques
GB0515703D0 (en) 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
GB2461874B (en) 2008-07-14 2012-11-21 Caltec Ltd Separation system and method
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
CA2782472C (en) * 2009-12-15 2019-04-16 The Hospital For Sick Children Method of treating scars and beta-catenin-mediated disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101171004A (zh) * 2005-04-04 2008-04-30 索塞R&D有限公司 奈福泮及其类似物的治疗用途
CN101002756A (zh) * 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
WO2009053742A2 (en) * 2007-10-25 2009-04-30 Sosei R & D Limited Salts of nefopam and their use in therapy

Also Published As

Publication number Publication date
US8957107B2 (en) 2015-02-17
US20150105363A1 (en) 2015-04-16
US20120294928A1 (en) 2012-11-22
CA2782472C (en) 2019-04-16
US10722493B2 (en) 2020-07-28
US9566263B2 (en) 2017-02-14
HK1174565A1 (zh) 2013-06-14
CN102781442A (zh) 2012-11-14
CA2782472A1 (en) 2011-06-23
ES2594900T3 (es) 2016-12-23
HK1224224A1 (zh) 2017-08-18
BR112012014471A2 (pt) 2017-06-06
WO2011072394A1 (en) 2011-06-23
JP2013513625A (ja) 2013-04-22
EP2512468A4 (en) 2013-08-07
US20170172980A1 (en) 2017-06-22
EP2512468A1 (en) 2012-10-24
JP5792185B2 (ja) 2015-10-07
EP2512468B1 (en) 2016-08-24
KR20120110117A (ko) 2012-10-09
CN105687185A (zh) 2016-06-22
KR101753439B1 (ko) 2017-07-19
DK2512468T3 (en) 2016-11-14
CN105687185B (zh) 2019-07-09
US20170281594A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CN102781442B (zh) 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
KR102077871B1 (ko) 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
Huang et al. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
JP7197370B2 (ja) がんの予防および／または治療のための化合物、組成物および方法
US20160213669A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
WO2020062951A1 (zh) 化合物及其用途
JP2019522652A (ja) Ｂｒａｆ阻害剤を用いる創傷治癒
CN104902901A (zh) 使用cbp/连环蛋白的抑制剂治疗过度增殖性和癌前皮肤病
EP3221284B1 (en) 13-cis-ramba retinamides that degrade mnks for treating cancer
WO2013149026A2 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
HK1224224B (zh) 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds
EP4501324A1 (en) Wound treatment composition
HK40116301A (en) Wound treatment composition
CN108779083B (zh) 作为细胞色素p450抑制剂的四唑衍生物
KR102168006B1 (ko) 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
HK40114947A (zh) 创伤治疗用组合物
WO2024192252A2 (en) Use of small molecules to increase hypoxia inducible factor (hif) activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174565

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1174565

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160217

Termination date: 20201215